Adamas Pharmaceuticals

Adamas is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system (CNS). We achieve this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.
Company Growth (employees)
Type
Public
HQ
Emeryville, US
Founded
2002
Size (employees)
69 (est)+12%
Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US

Key People at Adamas Pharmaceuticals

William Dawson

William Dawson

CFO
David Chernoff

David Chernoff

Chief Medical Officer
David Mahoney

David Mahoney

Director
Mary Jean Stempien

Mary Jean Stempien

VP, Clinical Research

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville
Emeryville, US (HQ)
750 1900 Powell St

Adamas Pharmaceuticals Metrics

Adamas Pharmaceuticals Financial Metrics

Revenue (2016)

$572 k

Revenue growth (2015-16), %

(70%)

Net income (2016)

($60.1 m)

Market capitalization (21-Mar-2017)

$389.3 m

Closing share price (21-Mar-2017)

$17.7

Cash (31-Dec-2016)

$23.7 m
Adamas Pharmaceuticals's current market capitalization is $389.3 m.
Adamas Pharmaceuticals's revenue was reported to be $572 k in FY, 2016 which is a 70.1% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$55.8 m$1.9 m$572 k

Revenue growth, %

(97%)(70%)

R&D expense

$21.9 m$35.9 m$31.2 m

General and administrative expense

$15.5 m$23.5 m

Operating expense total

$37.3 m$59.4 m$61.6 m

EBIT

$18.5 m($57.4 m)($61 m)

EBIT margin, %

33%(2998%)(10662%)

Interest income

($917 k)$363 k$811 k

Pre tax profit

$17.6 m($57.1 m)($60.2 m)

Income tax expense

($7.4 m)($5.3 m)($115 k)

Net Income

$10.2 m($51.8 m)($60.1 m)
FY, 2014FY, 2015FY, 2016

Cash

$61.4 m$33.1 m$23.7 m

Inventories

$269.8 m

Current Assets

$123.5 m$113.2 m$117 m

PP&E

$1.2 m$2.4 m$3.2 m

Total Assets

$161.2 m$128.7 m$142.5 m

Accounts Payable

$111.9 m

Current Liabilities

$12.5 m$11.8 m$9.7 m

Non-Current Liabilities

$749 k$547 k

Total Liabilities

$12.6 m$10.3 m

Additional Paid-in Capital

$157.6 m$178.5 m$254.6 m

Retained Earnings

($10.3 m)($62.2 m)($122.2 m)

Total Equity

$147.1 m$116.2 m$132.2 m

Financial Leverage

1.1 x1.1 x1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

$10.2 m($51.8 m)($60.1 m)

Depreciation and Amortization

$155 k$435 k$808 k

Accounts Receivable

($70.7 m)($42.3 m)$29.4 m

Inventories

($97.8 m)($153.7 m)$2.1 m

Accounts Payable

$28.2 m$16 m$14.4 m

Cash From Operating Activities

($24.2 m)($28.3 m)($48.1 m)

Purchases of PP&E

($1.3 m)($1.4 m)($1.6 m)

Cash From Investing Activities

($97.4 m)$8.1 m($26.7 m)

Cash From Financing Activities

$47 m$10.8 m$65.4 m

Interest Paid

$279 k$279 k

Income Taxes Paid

$341 k$4.7 m

Adamas Pharmaceuticals Market Value History

Adamas Pharmaceuticals Company Life

You may also be interested in